Silence Therapeutics has appointed Dave Lemus to its Board as non-executive director and Richard Jenkins as head of clinical development. Dave has over 20 years of US and international business experience in the pharmaceutical and biotechnology industries, having served in executive management and non-executive board roles in multiple US and European private and publicly-traded companies. He is currently executive vice chair, chief operating officer and CFO of Proteros biostructures. He also currently serves as a non-executive board member of BioHealth Innovation, Sorrento Therapeutics, and the MIT Club of Washington DC.

Richard Jenkins has over 28 years’ experience in clinical development and drug discovery, and will be heading the clinical development function as Silence advances its lead asset through the clinic. He has held numerous leadership positions in big pharma throughout his career. Richard most recently served as senior scientific director at Takeda Development Centre (Europe) where he was global clinical development team leader for development of Takeda’s upper GI compounds.